Endurant Capital Management LP Sutro Biopharma, Inc. Transaction History

Endurant Capital Management LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$5.41 - $8.08 $82,318 - $122,945	15,216 Added 5.71%	281,895 $2.28 Million
Q3 2022 Nov 14, 2022	SELL	$5.17 - $7.11 $469,363 - $645,488	-90,786 Reduced 25.4%	266,679 $1.48 Million
Q2 2022 Aug 15, 2022	BUY	$3.41 - $8.95 $207,863 - $545,565	60,957 Added 20.56%	357,465 $1.86 Million
Q1 2022 May 16, 2022	BUY	$7.78 - $15.31 $1.44 Million - $2.83 Million	184,705 Added 165.21%	296,508 $2.44 Million
Q4 2021 Feb 14, 2022	BUY	$14.25 - $23.53 $1.59 Million - $2.63 Million	111,803 New	111,803 $1.66 Million
Q1 2021 May 17, 2021	SELL	$20.29 - $27.54 $3.49 Million - $4.74 Million	-172,047 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$10.16 - $23.98 $2.95 Million - $6.96 Million	-290,123 Reduced 62.77%	172,047 $3.74 Million
Q3 2020 Nov 16, 2020	BUY	$7.44 - $13.15 $2.28 Million - $4.03 Million	306,165 Added 196.25%	462,170 $4.65 Million
Q2 2020 Aug 14, 2020	BUY	$7.24 - $11.05 $1.13 Million - $1.72 Million	156,005 New	156,005 $1.21 Million
Q1 2020 May 15, 2020	SELL	$6.19 - $12.16 $202,202 - $397,218	-32,666 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$8.15 - $11.39 $266,227 - $372,065	32,666 New	32,666 $359,000

137

62.4M

77.1K

31.4K

Ticker STRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,161,500
Market Cap $105M
Description
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-dr...

Get notified when there are updates to the investment portfolio of Endurant Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Endurant Capital Management LP with notifications on news.